{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:54:08Z","timestamp":1776387248924,"version":"3.51.2"},"reference-count":17,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T00:00:00Z","timestamp":1617753600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.clinthera.2021.04.002","type":"journal-article","created":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T10:09:58Z","timestamp":1624270198000},"page":"1051-1065","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Celecoxib-tramadol co-crystal: A Randomized 4-Way Crossover Comparative Bioavailability Study"],"prefix":"10.1016","volume":"43","author":[{"given":"Jes\u00fas","family":"Cebrecos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James D.","family":"Carlson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregorio","family":"Encina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mounia","family":"Lahjou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Artur","family":"Sans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariano","family":"Sust","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Vaqu\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adelaida","family":"Morte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neus","family":"Gasc\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Plata-Salam\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2021.04.002_bib0001","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/ACO.0000000000000225","article-title":"Acute pain assessment tools: let us move beyond simple pain ratings","volume":"28","author":"Gordon","year":"2015","journal-title":"Curr Opin Anaesthesiol"},{"key":"10.1016\/j.clinthera.2021.04.002_bib0002","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.2146\/ajhp140541","article-title":"Pathophysiology, assessment, and management of pain in critically ill adults","volume":"72","author":"Reardon","year":"2015","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.clinthera.2021.04.002_bib0003","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1185\/03007995.2013.860019","article-title":"Incidence, patient satisfaction, and perceptions of post-surgical pain: results from a US national survey","volume":"30","author":"Gan","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2021.04.002_bib0004","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s40122-017-0090-5","article-title":"A review of current and emerging approaches to pain management in the emergency department","volume":"6","author":"Todd","year":"2017","journal-title":"Pain Ther"},{"key":"10.1016\/j.clinthera.2021.04.002_bib0005","doi-asserted-by":"crossref","first-page":"6","DOI":"10.7453\/gahmj.2014.075","article-title":"The need for preventing chronic pain: the \u201cbig elephant in the room\u201d of healthcare","volume":"4","author":"Fricton","year":"2015","journal-title":"Global Advances in Health and Medicine"},{"key":"10.1016\/j.clinthera.2021.04.002_bib0006","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jpain.2015.12.008","volume":"17","author":"Chou","year":"2016","journal-title":"J Pain"},{"key":"10.1016\/j.clinthera.2021.04.002_bib0007","series-title":"Pain Management Best Practices Inter-Agency Task Force Report: updates, gaps, inconsistencies, and recommendations. Retrieved from U. S. Department of Health and Human Services website:","year":"2019"},{"key":"10.1016\/j.clinthera.2021.04.002_bib0008","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.jpain.2009.12.010","article-title":"The determination and application of fixed-dose analgesic combinations for treating multimodal pain","volume":"11","author":"Raffa","year":"2010","journal-title":"J Pain"},{"key":"10.1016\/j.clinthera.2021.04.002_bib0009","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.drudis.2016.02.001","article-title":"Multidrug cocrystals: towards the development of effective therapeutic hybrids","volume":"21","author":"Thipparaboina","year":"2016","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.clinthera.2021.04.002_bib0010","series-title":"Regulatory Classification of Pharmaceutical Co-Crystals Guidance for Industry","year":"2018"},{"key":"10.1016\/j.clinthera.2021.04.002_bib0011","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.2147\/JPR.S208082","article-title":"Co-crystals as a new approach to multimodal analgesia and the treatment of pain","volume":"12","author":"Almansa","year":"2019","journal-title":"J Pain Res"},{"key":"10.1016\/j.clinthera.2021.04.002_bib0012","unstructured":"Celebrex\u00ae label (2021). Pfizer Inc. Retrieved 04\/2021 from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/020998s056lbl.pdf."},{"key":"10.1016\/j.clinthera.2021.04.002_bib0013","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0022-3565(25)11227-5","article-title":"Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an \u2018atypical\u2019 opioid analgesic","volume":"260","author":"Raffa","year":"1992","journal-title":"J Pharm and Experimental Therapeutics"},{"key":"10.1016\/j.clinthera.2021.04.002_bib0014","unstructured":"Ultram\u00ae label (2021). Janssen Pharmaceuticals, Inc. Retrieved 04\/2021 from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/020281s048lbl.pdf."},{"key":"10.1016\/j.clinthera.2021.04.002_bib0015","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1111\/bcp.13395","article-title":"Single-dose pharmacokinetics of co-crystal of tramadol-celecoxib: results of a four-way randomized open-label phase I clinical trial in healthy subjects","volume":"83","author":"Videla","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2021.04.002_bib0016","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/bcp.13428","article-title":"Pharmacokinetics of multiple doses of co-crystal of tramadol-celecoxib: findings from a four-way randomized open-label phase I clinical trial","volume":"84","author":"Videla","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2021.04.002_bib0017","unstructured":"Entresto\u00ae label (2021). Novartis Pharmaceuticals Corporation, Retrieved 04\/2021 from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/207620s018lbl.pdf."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291821001624?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291821001624?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:54:54Z","timestamp":1758963294000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291821001624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S0149291821001624"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.04.002","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Celecoxib-tramadol co-crystal: A Randomized 4-Way Crossover Comparative Bioavailability Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}